ATE333284T1 - Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon - Google Patents

Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon

Info

Publication number
ATE333284T1
ATE333284T1 AT00965477T AT00965477T ATE333284T1 AT E333284 T1 ATE333284 T1 AT E333284T1 AT 00965477 T AT00965477 T AT 00965477T AT 00965477 T AT00965477 T AT 00965477T AT E333284 T1 ATE333284 T1 AT E333284T1
Authority
AT
Austria
Prior art keywords
ifn
methods
immunostimulative
alpha
nucleic acids
Prior art date
Application number
AT00965477T
Other languages
English (en)
Inventor
Gunther Hartmann
Robert L Bratzler
Arthur Krieg
Original Assignee
Coley Pharm Group Inc
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22558308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE333284(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coley Pharm Group Inc, Univ Iowa Res Found filed Critical Coley Pharm Group Inc
Application granted granted Critical
Publication of ATE333284T1 publication Critical patent/ATE333284T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
AT00965477T 1999-09-27 2000-09-27 Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon ATE333284T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15614799P 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
ATE333284T1 true ATE333284T1 (de) 2006-08-15

Family

ID=22558308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965477T ATE333284T1 (de) 1999-09-27 2000-09-27 Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon

Country Status (12)

Country Link
EP (1) EP1220684B2 (de)
JP (1) JP2003510290A (de)
AT (1) ATE333284T1 (de)
AU (1) AU783118B2 (de)
CA (1) CA2386019C (de)
DE (1) DE60029460T3 (de)
ES (1) ES2265980T5 (de)
IL (1) IL148844A0 (de)
MX (1) MXPA02003059A (de)
NZ (1) NZ517928A (de)
WO (1) WO2001022990A2 (de)
ZA (1) ZA200201959B (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001012223A2 (en) 1999-08-19 2001-02-22 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2001231245A1 (en) 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
CA2399550A1 (en) 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
DK1366077T3 (da) 2000-09-15 2011-09-12 Coley Pharm Gmbh Fremgangsmåde til screening i store mængder af CpG-baserede immunoagonister/-antagonister
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
PT1404873E (pt) 2001-06-21 2013-07-30 Dynavax Tech Corp Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
EP1450856B1 (de) 2001-09-14 2009-11-11 Cytos Biotechnology AG VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
WO2003089642A1 (en) * 2002-04-22 2003-10-30 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
AU2003247880B2 (en) * 2002-07-03 2010-09-02 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
SG166673A1 (en) * 2002-08-19 2010-12-29 Coley Pharm Group Inc Immunostimulatory nucleic acids
JP2006515277A (ja) * 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Ｃ型肝炎ウィルス感染の処置および予防に関する方法および製品
US7758876B2 (en) 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
PT1575977E (pt) 2002-12-23 2009-12-15 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
BRPI0408623A (pt) * 2003-03-26 2006-03-07 Cytos Biotechnology Ag conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
WO2004094448A1 (ja) * 2003-04-23 2004-11-04 Taisho Pharmaceutical Co. Ltd. メチル化ＣｐＧポリヌクレオチド
CA2527756C (en) * 2003-05-15 2014-05-06 Japan Science And Technology Agency Immunostimulating agents
JP3976742B2 (ja) * 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
JP2008000001A (ja) * 2004-09-30 2008-01-10 Osaka Univ 免疫刺激オリゴヌクレオチドおよびその医薬用途
DE102005005642A1 (de) * 2005-02-06 2006-08-10 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CA2612162C (en) 2005-07-01 2016-05-17 Index Pharmaceuticals Ab Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
US8148341B2 (en) 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids
EP1929014B1 (de) * 2005-08-31 2014-08-13 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verfahren zur änderung einer durch cpg-oligodesoxynukleotide des d-typen induzierten immunantwort
WO2007050034A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP2883957A1 (de) 2005-11-25 2015-06-17 Zoetis Belgium S.A. Immunstimulierende Oligoribonukleotide
EP1973608A1 (de) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunstimulatorische nukleinsäure-packteilchen zur behandlung von überempfindlichkeit
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2007139190A1 (ja) 2006-05-31 2007-12-06 Toray Industries, Inc. 免疫刺激オリゴヌクレオチド及びその医薬用途
AU2007260236B2 (en) 2006-06-12 2013-05-16 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
EP1920775B1 (de) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5' Triphosphat -oligonukleotid induziert eine antivirale Reaktion
EP3342415B1 (de) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur und verwendung von 5´-phosphat-oligonukleotiden
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2104738A2 (de) * 2006-10-26 2009-09-30 Coley Pharmaceuticals GmbH Oligoribonukleotide und ihre verwendung
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
AU2008252577A1 (en) 2007-05-17 2008-11-27 Coley Pharmaceutical Gmbh Class A oligonucleotides with immunostimulatory potency
ES2544484T3 (es) 2007-05-18 2015-08-31 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante
DE102007044093A1 (de) * 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
EP3085377A1 (de) 2008-01-25 2016-10-26 Chimerix, Inc. Verfahren zur behandlung von virusinfektionen
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
NZ601345A (en) 2008-10-16 2014-05-30 Univ Dalhousie Combination adjuvant formulation
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
EP2376108B1 (de) 2008-12-09 2017-02-22 Pfizer Vaccines LLC Ige ch3 peptidimpstoff
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2451461A4 (de) 2009-07-06 2013-05-29 Ontorii Inc Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
EP2534150B1 (de) 2010-02-12 2017-04-05 Chimerix, Inc. Verfahren zur behandlung von vireninfektionen
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
NZ603527A (en) 2010-05-28 2014-10-31 Zoetis Belgium S A Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
EP2620428B1 (de) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
EP2680883B1 (de) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9-impfstoff
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
CN109912602A (zh) 2011-06-01 2019-06-21 贾纳斯生物治疗有限公司 新型免疫系统调节剂
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
WO2013007703A1 (en) 2011-07-08 2013-01-17 Universität Zürich CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
RU2677639C2 (ru) * 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Хиральный адъювант нуклеиновой кислоты
PL2872147T3 (pl) 2012-07-13 2023-09-25 Wave Life Sciences Ltd. Sposób wytwarzania chiralnych oligonukleotydów
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (ja) * 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (de) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CN107108629A (zh) 2014-08-22 2017-08-29 贾纳斯生物治疗有限公司 新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法
WO2017121494A1 (en) * 2016-01-15 2017-07-20 Riboxx Gmbh 5'-triphosphated short immunostimulatory nucleotides, oligonucleotides and polynucleotides
EP3452598A4 (de) 2016-05-06 2020-04-29 Exicure, Inc. Konstrukte aus liposomaler sphärischer nukleinsäure (sna) mit antisense-oligonukleotiden (aso) zum spezifischen knockdown von interleukin-17-rezeptor-mrna
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
WO2017210647A1 (en) 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CR20200260A (es) * 2017-12-15 2020-08-01 Bayer Animal Health Gmbh Composiciones inmunoestimulantes
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN112423766A (zh) * 2018-07-19 2021-02-26 一般财团法人阪大微生物病研究会 含有A型CpG寡脱氧核糖核苷酸的脂质颗粒
EP3909612A1 (de) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Zusammensetzung von nanopartikeln

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2000006588A1 (en) * 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS

Also Published As

Publication number Publication date
ZA200201959B (en) 2003-05-28
AU7619000A (en) 2001-04-30
CA2386019C (en) 2011-06-21
MXPA02003059A (es) 2002-09-30
NZ517928A (en) 2004-09-24
ES2265980T3 (es) 2007-03-01
EP1220684B2 (de) 2010-07-14
DE60029460T2 (de) 2007-03-15
DE60029460D1 (de) 2006-08-31
EP1220684B1 (de) 2006-07-19
EP1220684A2 (de) 2002-07-10
WO2001022990A2 (en) 2001-04-05
IL148844A0 (en) 2002-09-12
CA2386019A1 (en) 2001-04-05
JP2003510290A (ja) 2003-03-18
WO2001022990A3 (en) 2001-10-04
AU783118B2 (en) 2005-09-29
ES2265980T5 (es) 2010-12-28
DE60029460T3 (de) 2011-02-10

Similar Documents

Publication Publication Date Title
ATE333284T1 (de) Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
KR101107818B1 (ko) 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
JP4989225B2 (ja) 核酸親油性接合体
EP1764107A1 (de) Zusammensetzungen enthaltend immunstimulierende RNA-Oligonukleotide und Methoden zu deren Herstellung
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
AU4328801A (en) Simultaneous stimulation and concentration of cells
IL160157A (en) Combination motif immune stimulatory oligonucleotides with improved activity
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
KR20060033911A (ko) 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
EP2292771A3 (de) Sense mRNA Therapie
EP1712243A4 (de) Gentherapie gegen tumoren mit minus-strang-rna-virusvektoren, die für immunstimulatorische zytokine codieren
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
AU5896098A (en) Inhibitors of interleukin-1beta converting enzyme
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
EP2327722A3 (de) An Vireninfektions- und Tumorsuppression beteiligte Säugetiergene
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
WO2003022225A3 (en) Compositions comprising mixtures of therapeutic proteins and methods of producing the same
WO2002068629A3 (en) Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
WO2003044183A8 (en) Interleukin-2 gene transferred lymphokine activated killer cells
Luo The effects of 2', 3'-dideoxynucleosides on duck hepatitis B virus replication: A model for inhibition of hepadnavirus replication.
EP1849480A3 (de) Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties